• Sist endret: 07.12.2012
  • Sist revidert: 07.12.2012

Vil du vite mer?

Dette dokumentet er basert på det profesjonelle dokumentet "Crohns sykdom" i Norsk Elektronisk Legehåndbok. Referanselisten for dette dokumentet vises nedenfor.

Referanser

  1. Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn's disease. Am Fam Physician 2011; 84: 1365-75. AFP
  2. Hanauer SB, Sanborn W. The management of Crohn's disease in adults. Am J Gastroenterol 2001; 96: 635-43. PubMed
  3. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5: 1424-9. PubMed
  4. Knutson D, Greenberg G, Cronau H. Management of Crohn's disease - a practical approach. Am Fam Physician 2003; 68: 707-18. AFP
  5. Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev 2003; 2: 346-57. PubMed
  6. Halme L, Paavola-Sakki P, Turunen U, et. al. Family and twin studies in inflammatory bowel disease. World J Gastroenterol 2009; 12: 3668-72. PubMed
  7. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29. NEJM
  8. Moum B. Prognose og behandling ved kronisk inflammatorisk tarmsykdom. Tidsskr Nor Lægeforen 2001; 121: 318-21. Tidsskriftet
  9. Hampe J, Cuthbert A, Croucher PJP, Mirza MM et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations . Lancet 2001; 357: 1925-8. PubMed
  10. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-78. NEJM
  11. Takeuchi K, Smale S, Premchand P, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 196-202. PubMed
  12. Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69: 2277-85. PubMed
  13. Feagan BG. Maintenance therapy for inflammatory bowel disease. Am J Gastroenterol 2003; 98: 6-17. PubMed
  14. Moum B. Ulcerøs kolitt, Crohns sykdom og 5-aminosalisylsyreforbindelser. Tidsskr Nor Lægeforen 2003; 123: 2565-7. Tidsskriftet
  15. Logan RFA. Inflammatory bowel disease incidence: up, down or unchanged? Gut 1998; 42: 309 - 11. Gut
  16. Tibble J, Teahon K, Thjodleifsson B, Roseth A, Sigthorsson G, Bridger S, Foster R, Sherwood R, Fagerhol M, Bjarnason I. A simple methood for assessing intestinal inflammation in Crohns's disease. Gut 2000; 47: 506-13 Gut
  17. Jahnsen J, Røseth AG, Aadland A. Måling av kalprotektin i feces. Tidsskr Nor Legeforen 2009; 129: 743-5. Tidsskriftet
  18. van Rheenen PF, de Vijver EV, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369. BMJ
  19. Stange EF, Travis SP, Vermeire S, et al.; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55(suppl 1): i1–i15.
  20. Solem CA, Loftus EV Jr, Fletcher JG, et al. Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc 2008; 68: 255-66. PubMed
  21. Horsthuis K, Bipat S, Bennink RJ, Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: meta-analysis of prospective studies. Radiology 2008; 247: 64-79. Radiology
  22. Eriksen R, Qvigstad T. Ultrasonografi ved inflammatoriske tarmsykdommer - foreløpige erfaringer Tidsskr Nor Lægeforen 2002; 122: 2594 - 7.
  23. Skaane P, Schistad O, Amland PF, Solheim K. Routine ultrasonography in the diagnosis of acute appendicitis: a valuable tool in daily practice? Am Surg 1997; 63: 937 - 42. PubMed
  24. Potthast S, Rieber A, von Tirpitz C, Wruk D, Adler G, Brambs HJ. Ultrasound and magnetic resonance imaging in Crohn's disease: a comparison. Eur Radiol 2002; 12: 1416 - 22. PubMed
  25. Tøttrup A, Basu D. Kirurgisk behandling af Crohns sygdom. Ugeskr Læger 2004; 166: 571-4. Ugeskrift
  26. Steinhart AH, Ewe K, Griffiths AM et al. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2003, Issue 4. Cochrane
  27. Feagan BG. Maintenance therapy for inflammatory bowel disease. Am J Gastroenterol 2003; 98: 6-17. PubMed
  28. Cosnes J, Beaugerie L, Carbonnel F et al. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001;120:1093-9. Gastro
  29. Kelly D, Fleming R. Nutritional considerations in inflammatory bowel disease. Gastroenterol Clin North Am 1995; 24: 597-.
  30. Martinsen TC, Herter R, Dybdahl JH, Waldum H. Bruk av TNF-α-antistoff ved inflammatorisk tarmsykdom. Tidsskr Nor Legeforen 2010; 130: 273-7. Tidsskriftet
  31. Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Chrohn's disease. Cochrane Database of Systematic Reviews 2008; Issue 3. Cochrane
  32. Hanauer SB, Strömberg U. Oral Pentasa in the treatment of active Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 379-88. PubMed
  33. Egan LJ, Sandborn WJ. Advances in the treatment of Crohn's disease. Gastroenterology 2004; 126: 1574-81. Gastro
  34. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2009, 7 Oct. CD003715. Cochrane
  35. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: doi:10.1016/S0140-6736(09)61302-7 .
  36. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn`s disease: Results of the ENCORE trial. Gastroenterology 2007; 132: 1672-83. Gastro
  37. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405. NEJM
  38. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of emission in Crohn’s disease (Cochrane Review). I: The Cochrane Library, Issue 1, 2004. Oxford: Update Software. Cochrane
  39. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876 - 85. NEJM
  40. Farmer RG, Hawk WA, Turnbull RB, Jr. Indications for surgery in Crohn's disease: analysis of 500 cases. Gastroenterology 1976;71:245-50. Gastro
  41. Tøttrup A. Laparoskopisk kirurgi ved inflammatorisk tarmsygdom. Ugeskr Læger 2010; 172: 2287. Ugeskrift
  42. Post S, Herfarth C, Bohm E et al. The impact of disease pattern, surgical management, and individual surgeons on the risk for relaparotomy for recurrent Crohn's disease. Ann Surg 1996;223:253-60. PubMed
  43. Alexander-Williams J, Haynes IG. Conservative operations for Crohn's disease of the small bowel. World J Surg 1985;9:945-51. PubMed
  44. Smedh K, Olaison G, Nystrom PO et al. Intraoperative enteroscopy in Crohn's disease. Br J Surg 1993;80:897-900. PubMed
  45. Tonelli F, Ficari F. Strictureplasty in Crohn's disease: surgical option. Dis Colon Rectum 2000;43:920-6. PubMed
  46. Delaney CP, Fazio VW. Crohn's disease of the small bowel. Surg Clin North Am 2001;81:137-58. PubMed
  47. Fazio VW, Marchetti F, Church M et al. Effect of resection margins on the recurrence of Crohn's disease in the small bowel. A randomized controlled trial. Ann Surg 1996;224:563-71. PubMed
  48. Heuman R, Boeryd B, Bolin T et al. The influence of disease at the margin of resection on the outcome of Crohn's disease. Br J Surg 1983;70:519-21. PubMed
  49. Schwartz DA, Wiersema MJ, Dudiak KM et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn's perianal fistulas. Gastroenterology 2001;121:1064-72. Gastro
  50. Lochs H, Mayer M, Fleig WE et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European cooperative Crohn's disease study VI. Gastroenterology 2000; 118: 264-73. Gastro
  51. Feagan BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease. The EPIC randomized controlled trials. JAMA 2008; 299: 1690-7. JAMA
  52. Klotz U. The role of aminosalicylates at the beginning of the new millenium in the treatment of chronic inflammatory bowel disease. Eur J Clin Pharmacol 2000; 56: 353 - 62. PubMed
  53. Gisbert JP, Gomollon F, Mate J, Pajares JM. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease. A systematic review. Dig Dis Sci 2002; 47: 471 - 88. PubMed
  54. Lochs H. Mayer M, Fleig WE, Mortensen PB, Bauer P et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine. Gastroenterology 2000; 118: 264 - 73. Gastro
  55. Munck LK. Paradigmeskift i medicinsk behandling af Crohns sygdom. Ugeskr Læger 2005; 167: 3013. Ugeskrift
  56. Cottone M, Camma C, Sutherland LR. Mesalamine and relapse prevention in Crohns disease. Gastroenterology 2000; 116: 597. Gastro
  57. Rutgeerts P. Infliximab for ulcerative colitis: the need for adequately powered placebo-controlled trials. Am J Gastroenterol 2002; 10: 2488 - 9. PubMed
  58. Lofthus EV, Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002; 16: 51-60. PubMed
  59. Kleveland PM. Barn og unge med ulcerøs kolitt og Crohns sykdom. Tidsskr Nor Lægeforen 1998; 118: 2160-2. PubMed
  60. Moum B. Svangerskap og fødsel ved ulcerøs kolitt og Crohns sykdom. Tidsskr Nor Lægeforen 2001; 121: 322-5. Tidsskriftet
  61. Mayberry JF, Weterman IT. European survey and pregnancy in women with ulcerative colitis and Crohn's disease: a case control study by European collaborative group. Gut 1986;27: 821-5. Gut
  62. Nørgård B, Pedersen L, Christensen LA, Sørensen HT. Therapeutic drug use in women with Crohn`s disease and birth outcomes: a danish nationwide cohort study. Am J Gastroenterol 2007; 102: 1406-13. PubMed
  63. Sutherland LR. Maintenance therapy for inflammatory bowel disease: what really works. Can J Gastroenterol 1997; 11: 261-4. PubMed
  64. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity course in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706. PubMed
  65. Ewe K, Herfarth C, Malchow H, Jesdinsky HJ. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulphasalazine prophylaxis: a multicenter trial. Digestion 1989; 42: 224-32. PubMed
  66. King TS, Woolner JT, Hunter JO. Review article: the dietary management of Crohn's disease. Aliment Pharmacol Ther 1997; 11: 17-31. PubMed
  67. Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding factors. Gastroenterology 1997; 113: 1465-73. Gastro
  68. Sutherland LR. Aminosalicylates in the treatment of ulcerative colitis and Crohn's disease. I: Rutgeerts P, Colombel J-F, Hanauer SB, Schölmerich J, Tytgat GNJ, van Gossum A, red. Advances in inflammatory bowel diseases. Dordrecht: Kluwer, 1999: 201 - 9.
  69. Prakash A, Markham A. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. Drugs 1999; 57: 383 - 408. PubMed
  70. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Oxford: The Cochrane Library. Last amendment: 20 August 1998 Cochrane
  71. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-Mercaptopurine for inducing remission of Crohn's disease. Oxford: The Cochrane Library. Last amendment: 02 April 1998 Cochrane
  72. Löfberg R, Rutgeerts P, Lachow H, Lamers C, Danielson Å, Olison G et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo-controlled, one year study. Gut 1996; 39: 82-6. Gut
  73. Rutgeerts P. Medical therapy of inflammatory bowel disease. Digestion 1998; 59: 453-69. PubMed
  74. Present DH. How to do without steroids in inflammatory bowel disease. Inflamm Bowel Dis 2000; 6:James AL, Burton MJ. Betahistine for Menières disease or syndrome (Cochrane Review). In: The Cochrane Library, Issue 1, 2001. Oxford: Update Software. 48-57. Cochrane
  75. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor for Crohn's disease. N Engl J Med; 1997; 337: 1029-35.
  76. Present DH, Rutgeerts P, Targan S, Hanauer SB, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405. NEJM
  77. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9. Gastro
  78. Orholm M, Munkholm P, Langholz E, Nielsen OH, Sørensen TIA, Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991; 324: 84-8. NEJM
  • Aabakken L, Carlsen E. Gastroenterologiske rutiner ved Ullevål sykehus. 6. utgave. Oslo: 2000.
Spør legen

Debattregler

Relaterte artikler

Relaterte artikler

Crohns sykdom

Crohns sykdom er en kronisk betennelse i mage-tarmkanalen. Mange går med plager ...

Crohns sykdom, kirurgi

Crohns sykdom Crohns sykdom er en kronisk betennelsessykdom i fordøyelseskanalen ...

Crohns sykdom, legemidler

Crohns sykdom Crohns sykdom er en kronisk betennelsessykdom i fordøyelseskanalen ...

Crohns sykdom, årsaker

Crohns sykdom er en kronisk betennelsessykdom i fordøyelseskanalen som særlig ...

Inflammatorisk tarmsykdom, kosthold

Hva er inflammatorisk tarmsykdom? Inflammatorisk tarmsykdom er en kronisk betennelse i tarmen....

NHI.no - Norges største helsenettside. Basert på Nordens mest brukte oppslagsverk for leger og helsepersonell (Norsk Elektronisk Legehåndbok).

©2011 Norsk Helseinformatikk AS. Alle rettigheter er reservert. All informasjon på NHI.no er laget for å gi deg generell kunnskap og er ingen erstatning for innhenting av medisinsk råd eller behandling hos helsepersonell. Dersom du er syk eller trenger medisinsk hjelp av andre grunner, bør du oppsøke lege. NHI er uten ansvar for innholdet på eksterne websteder det er lenket til. Vi tillater ikke reklame for behandlere/ behandlingsmetoder i kommentarfeltene. Alle slike innlegg vil bli slettet.